News

Honors and Awards January 26, 2023

Damon Runyon Cancer Research Foundation Awards over $4.3M to Top Young Scientists

The Damon Runyon Cancer Research Foundation has announced its newest class of Damon Runyon Fellows, 14 exceptional postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators. The prestigious, four-year Fellowship encourages the nation’s most promising young scientists to pursue careers in cancer research by providing them with independent funding ($260,000 total) to investigate cancer causes, mechanisms, therapies, and prevention.

Honors and Awards January 18, 2023

Damon Runyon awards $3.2M to innovative early-career scientists

The Damon Runyon Cancer Research Foundation has announced eight recipients of the 2023 Damon Runyon-Rachleff Innovation Award, established to support “high-risk, high-reward” ideas with the potential to significantly impact the prevention, diagnosis, or treatment of cancer. Five extraordinary early-career researchers will receive initial grants of $400,000 over two years, and each will have the opportunity to receive two additional years of funding (for a potential total of $800,000).

Honors and Awards August 22, 2022

Damon Runyon welcomes new Board Member

Damon Runyon is excited to announce the election of Joseph Pearlberg, MD, PhD, to its Board of Directors.

Honors and Awards August 12, 2022

Damon Runyon Clinical Investigator Award Committee member Monica Bertagnolli, MD, to serve as National Cancer Institute Director

President Biden has announced his intent to appoint Clinical Investigator Award Committee member Monica Bertagnolli, MD, as Director of the National Cancer Institute. Dr. Bertagnolli will be the 16th Director, and the first woman, to head the NCI.

Honors and Awards August 4, 2022

Damon Runyon welcomes new Board Member

Damon Runyon is delighted to announce the election of Lori J. Pierce, MD, to its Board of Directors.

Honors and Awards July 28, 2022

Damon Runyon Cancer Research Foundation awards over $4.1 million to exceptional early-career scientists

The Damon Runyon Cancer Research Foundation has named 16 new Damon Runyon Fellows, exceptional postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators. The prestigious, four-year Fellowship encourages the nation's most promising young scientists to pursue careers in cancer research by providing them with independent funding ($260,000 total) to investigate cancer causes, mechanisms, therapies, and prevention.

Honors and Awards July 18, 2022

Damon Runyon Cancer Research Foundation announces Fellowship stipend increase

Amid growing calls for academic and funding institutions to recognize the financial hardships faced by postdoctoral researchers across the country, the Damon Runyon Cancer Research Foundation has announced that it will increase its Fellowship stipend by 12.5% over the award’s four-year term. The stipend increase will be effective for all Damon Runyon Fellows whose awards begin or renew on or after July 1, 2022.

Honors and Awards July 6, 2022

Damon Runyon Cancer Research Foundation awards $4.2 million to top clinical investigators

The Damon Runyon Cancer Research Foundation has named five new Damon Runyon Clinical Investigators. The recipients of this prestigious award are outstanding, early-career physician-scientists conducting patient-oriented cancer research at major research centers under the mentorship of the nation's leading scientists and clinicians.

Honors and Awards June 21, 2022

Damon Runyon Cancer Research Foundation celebrates 75th Anniversary

The Damon Runyon Cancer Research Foundation celebrated 75 years of funding cancer research at Gotham Hall in New York on June 1, 2022. The event raised nearly $1 million to support promising early-career scientists pursuing innovative strategies to prevent, diagnose, and treat all forms of cancer.

Honors and Awards June 15, 2022

New immunotherapy receives FDA approval

Immune checkpoint inhibitors work by releasing the “brakes” on immune T cells, unleashing them upon cancer cells. After the discovery of two of these brakes, PD-1 and CTLA-4, and the subsequent cascade of drugs targeting them, the search for new checkpoints to target stalled. But this spring, the FDA approved a new melanoma drug called relatlimab, which targets LAG-3—the first new checkpoint in almost a decade.

Damon Runyon News